Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OABI
HoldHot AirOmniAb, Inc. · Healthcare · United States · $650M · Avg Vol: $8M/d
COMPANY DESCRIPTION
OmniAb, Inc. is a biotechnology company focused on providing a comprehensive suite of proprietary antibody discovery technologies, including genetically engineered animals and in vitro display systems. These platforms enable its partners to discover and develop novel therapeutic antibodies for a wide range of diseases. OmniAb holds a strong niche market position as a technology licensor, critical to the R&D efforts of numerous pharmaceutical and biotech companies globally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.1M | 34.2M | 26.4M | 18.7M | -31.9% | 38.5M | 35.0M | 43.5M | 52.6% |
| EPS | -0.26 | -0.51 | -0.61 | -0.57 | — | -0.36 | -0.37 | -0.30 | — |
| Shares | 115.2M | 116.9M | 121.6M | 144.3M | +25.2% | 145.4M | — | — | — |
| Debt | 25.8M | 25.6M | 23.2M | 20.3M | -7.6% | 18.9M | — | — | — |
| Equity | 341.4M | 314.6M | 287.6M | 267.0M | -7.9% | — | — | — | — |
| Op CF | -3.6M | 2.3M | -39.7M | -36.5M | — | -17.7M | — | — | — |
| Inv CF | -73.3M | -18.4M | 37.9M | 6.5M | — | — | — | — | — |
| Fin CF | 110.7M | -0.9M | 13.0M | 27.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OABI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OABI | OmniAb, Inc.(you) | $650M | 40 | Hold |
| ARVN | Arvinas, Inc. | $592M | 40 | Hold |
| CLYM | Climb Bio, Inc. | $837M | 40 | Hold |
| ARTV | Artiva Biotherapeutics, Inc. | $542M | 37 | Hold |
| GYRE | Gyre Therapeutics, Inc. | $699M | 34 | Sell |
| SGMT | Sagimet Biosciences Inc. | $656M | 32 | Sell |
| OVID | Ovid Therapeutics Inc. | $547M | 35 | Sell |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 30 | Sell |
| ASMB | Assembly Biosciences, Inc. | $694M | 31 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%